ArticleOncoimmunology2014
Antibody response to cancer/testis (CT) antigens: A prognostic marker in cancer patients.
Article in Oncoimmunology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 15 citations in OpenAlex.
- A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancer.Cancer immunology, immunotherapy : CII · 2019Trial
- Hydrophobicity and molecular mass-based separation method for autoantibody discovery from mammalian total cellular proteins.Protein science : a publication of the Protein Society · 2023Article
- Engineering Cancer/Testis Antigens With ReversibleFrontiers in oncology · 2022Article
- Ropporin-1 and 1B Are Widely Expressed in Human Melanoma and Evoke Strong Humoral Immune Responses.Cancers · 2021Article
- Post-operative unadjuvanted therapeutic xenovaccination with chicken whole embryo vaccine suppresses distant micrometastases and prolongs survival in a murine Lewis lung carcinoma model.Oncology letters · 2018Article
- Article
- Anti-NY-ESO-1 autoantibody may be a tumor marker for intrahepatic cholangiocarcinoma.Oncotarget · 2017Article
- Genome-wide identification of cancer/testis genes and their association with prognosis in a pan-cancer analysis.Oncotarget · 2017Article
- Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy.Journal for immunotherapy of cancer · 2017Review
- Enhancement of diagnostic performance in lung cancers by combining CEA and CA125 with autoantibodies detection.OncoimmunologyArticle
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune responses to tumor antigens have been reported in cancer patients. However, the relevance of such spontaneous immune responses to the clinical course has not been studied extensively. We showed that the overall survival of patients with antibodies against NY-ESO-1 or XAGE1 (GAGED2a) antigen was prolonged in gastric or lung cancer patients, respectively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.